Last year, the Supreme Court issued its opinion in Universal Health Services v. U.S. ex rel. Escobar, in which the Court affirmed the theory that violations of statutory and regulatory provisions can constitute actionable fraud under the False Claims Act (FCA). This webinar will explore different views on how this decision might affect FCA investigations and litigation in the coming years, including whether drug and device companies can expect more cases based on violations of provisions of the Federal Food, Drug & Cosmetic Act.
Jonathan M. Phillips, Associate Attorney, Gibson, Dunn & Crutcher LLP
Robert L. Vogel, Partner, Vogel, Slade & Goldstein LLP